SAB Biotherapeutics, Inc.(SABS)

Biotechnology · Miami Beach, FL

$2.97-0.13 (-4.05%)

Delayed quote: Oct 6, 2026, 1:15 PM EDT

SAB Biotherapeutics (SABS) OCF Yield: History & Chart | TGMCharts

Operating Cash Flow Yield: N/A

Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The operating cash flow yield is N/A as of 2026-10-06T17:18:03.848Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:18:03.848Z.

Quote observation: 2026-10-06T17:15:13.000Z. Amounts in USD. The price header may show a later quote.

TTM operating cash flow · period ending 2026-06-30: -68,209,480
Quote market capitalization: 270,620,754

FMP input reference: e4092e053989caac2e99517ddb979985c78622fc494c6088febce458b2dbbcab

P/OCF Ratio|FCF Yield|Earnings Yield|EBITDA Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SABS Operating Cash Flow Yield Metrics

OPERATING CASH FLOW YIELD

N/A

SABS Competitors' Operating Cash Flow Yield

SABS

SAB Biotherapeutics, Inc.

Current

Market Cap

$270.62M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TMCI

Treace Medical Concepts, Inc.

vs SABS

Market Cap

$270.52M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RCKT

Rocket Pharmaceuticals, Inc.

vs SABS

Market Cap

$271.35M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FATE

Fate Therapeutics, Inc.

vs SABS

Market Cap

$271.10M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLSI

TriSalus Life Sciences, Inc.

vs SABS

Market Cap

$269.06M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SCTX

Scribe Therapeutics Inc.

vs SABS

Market Cap

$267.65M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OSUR

OraSure Technologies, Inc.

vs SABS

Market Cap

$265.07M

Operating Cash Flow Yield

N/A

TTM Avg

17.72%

3Y Avg

21.01%

5Y Avg

14.11%

EPRX

Eupraxia Pharmaceuticals Inc.

vs SABS

Market Cap

$264.16M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EYPT

EyePoint Pharmaceuticals, Inc.

vs SABS

Market Cap

$262.74M

Operating Cash Flow Yield

N/A

TTM Avg

2.42%

3Y Avg

2.42%

5Y Avg

2.42%

IKT

Inhibikase Therapeutics, Inc.

vs SABS

Market Cap

$263.41M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	OPERATING CASH FLOW YIELD	TTM	3Y	5Y
SAB Biotherapeutics, Inc. (SABS)	$270.62M	N/A	N/A	N/A	N/A
Treace Medical Concepts, Inc. (TMCI)vs ›	$270.52M	N/A	N/A	N/A	N/A
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$271.35M	N/A	N/A	N/A	N/A
Fate Therapeutics, Inc. (FATE)vs ›	$271.10M	N/A	N/A	N/A	N/A
TriSalus Life Sciences, Inc. (TLSI)vs ›	$269.06M	N/A	N/A	N/A	N/A
Scribe Therapeutics Inc. (SCTX)vs ›	$267.65M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$265.07M	N/A	17.72%	21.01%	14.11%
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$264.16M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$262.74M	N/A	2.42%	2.42%	2.42%
Inhibikase Therapeutics, Inc. (IKT)vs ›	$263.41M	N/A	N/A	N/A	N/A

Operating Cash Flow Yield Formula & Definition

OCF Yield = TTM Operating Cash Flow / Market Cap

Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Operating Cash Flow Yield: N/A

SABS Operating Cash Flow Yield Metrics

SABS Competitors' Operating Cash Flow Yield

Operating Cash Flow Yield Formula & Definition

Related Metrics